FDA Guidance in 2026: What Every Regulatory Professional Needs to Know
- Entry to Regulatory
- 9 hours ago
- 9 min read
The regulatory affairs landscape has never been more dynamic — or more consequential. In 2026, the U.S. Food and Drug Administration (FDA) is navigating a period of profound transformation driven by budget pressures, technological disruption, biosimilar reform, and a rapidly evolving approach to evidence standards. For pharmaceutical companies, medical device manufacturers, and the professionals who support them, understanding these shifts is no longer optional. It is a strategic imperative.
This blog breaks down every major FDA guidance and policy shift of 2026, explains what it means for industry, and — critically — what it means for anyone looking to build or future-proof a career in regulatory affairs.
Launch Your Regulatory Affairs Career Faster Than You Think At Entry to Regulatory, we provide intensive, practical training courses for anyone looking to break into Regulatory Affairs — even with zero prior experience. Our programme covers EU, US, and UK regulations over 50+ CPD hours, pairs you with real-world work assignments, and gives you dedicated CV support, mock interviews, and job placement mentoring. Graduates are landing roles within weeks to months of completing the course. it. Speak to us and see how we can help you.
The Big Picture: Why 2026 Is a Pivotal Year for Regulatory Affairs
Before diving into specific policy changes, it is worth understanding the macro environment shaping the FDA's behaviour in 2026.
The agency is operating under unprecedented pressure from multiple directions simultaneously:
- Budget reductions under the current administration have resulted in an overall FDA budget of approximately $6.8 billion for FY2026 — a decrease of roughly $271 million (3.9%) year-on-year
- Staffing challenges from prior personnel restructuring have created a "brain drain" of experienced reviewers and inspectors, causing downstream delays in submissions and reviews
- Technological acceleration — particularly around artificial intelligence (AI) and real-world data — has forced the FDA to rapidly update its evidentiary standards and guidance frameworks
- Biosimilar reform has reached a new milestone with guidance that fundamentally changes the cost-structure of biologics development
The result is a regulatory environment where the rules are shifting, timelines are less predictable, and the premium on skilled regulatory professionals has never been higher.
1. FDA Staffing Challenges and the Impact on Submission Timelines
One of the most operationally significant shifts in 2026 is the ongoing disruption caused by FDA staffing reductions. Earlier restructuring efforts — part of wider federal workforce changes — led to the loss of a significant number of experienced FDA personnel, with HHS experiencing some of the most drastic reductions across government departments.
What This Means in Practice
- 510(k) medical device submissions are experiencing increased review delays. The Q-Sub (Pre-Submission) process has become an even more critical tool for companies looking to identify issues early and avoid costly back-and-forth
- Drug application reviews are subject to slower turnaround times as a reduced workforce manages a growing backlog
- Biologics and vaccine approvals have been particularly impacted, with delays in guidance meetings and fast-track programme access — especially for small biotechs
- The FDA's contingency staffing plan confirms 16,089 staff are maintained through September 30, 2026, with user fee-funded activities continuing regardless of any appropriations lapse
Business Implications
For sponsors and manufacturers, this means proactive regulatory strategy is now more valuable than ever. Companies that wait for FDA stability before preparing submissions are falling behind. Early engagement, pre-submission meetings, and meticulous documentation are the differentiators.
For regulatory professionals, this environment is creating urgent demand. Organisations that previously relied on lean internal teams now require specialist expertise at every stage of the development and approval lifecycle.
2. Artificial Intelligence in Drug Submissions: New Guiding Principles
The FDA — in collaboration with the European Medicines Agency (EMA) — has published 10 guiding principles for Good AI Practice (GAIP) in Drug Development, representing a landmark moment for the industry.
The 10 Guiding Principles at a Glance
1. Human-centric design — AI must support, not replace, clinical and regulatory judgement
2. Risk-based approaches — AI systems must be assessed proportionate to the risks they introduce
3. Adherence to standards — AI tools must comply with applicable regulatory frameworks
4. Clear context of use — The intended use of any AI model must be explicitly defined in submissions
5. Multidisciplinary expertise — AI development should involve cross-functional teams
6. Data governance and documentation — Full traceability of training data and model behaviour is expected
7. Best practices in model design — Models must be validated using established scientific methods
8. Risk-based performance assessment — Ongoing monitoring of AI performance is required
9. Life cycle management — AI systems must be managed across their operational life
10. Clarity in essential information — Submissions incorporating AI must be transparent and reproducible
What This Means for Industry
AI is no longer an edge case in regulatory submissions — it is becoming mainstream. The CDER has noted a growing incorporation of AI across all categories of drug application submissions. However, the FDA's approach is clear: AI must be explainable, validated, and documented to the same standards as any other scientific methodology.
Companies using AI in drug discovery, clinical trial design, or pharmacovigilance must now build regulatory strategy around these principles from day one — not as an afterthought.
For those entering the regulatory profession, understanding AI governance frameworks is rapidly becoming a baseline competency, not a specialism.
3. Real-World Evidence: From Supplementary to Central
Real-World Evidence (RWE) — data generated from sources outside traditional randomised controlled trials, such as electronic health records, insurance claims, and patient registries — has moved firmly into the mainstream of FDA decision-making in 2026.
Key Developments
- The FDA has expanded its framework for accepting RWE in regulatory submissions across multiple therapeutic areas
- RWE is increasingly being used to support label expansions, post-market safety studies, and even primary efficacy claims in certain contexts
- There is growing expectation that sponsors demonstrate how their RWE strategy aligns with both US and EU regulatory standards, reflecting increasing transatlantic regulatory convergence
Strategic Questions Sponsors Must Ask
The regulatory expectation around RWE is moving towards credibility and rigour. Sponsors should be asking:
- Is our data source fit for purpose and representative of the intended patient population?
- How do we ensure data integrity across external data platforms?
- Is our RWE methodology pre-agreed with the FDA, and if not, what is our engagement strategy?
- Have we aligned our RWE approach with EU requirements to support global submissions simultaneously?
The shift towards RWE represents a significant change in the skill set required of regulatory professionals — one that blends traditional regulatory science with epidemiology, data science, and strategic planning.
4. Biosimilar Development: The March 2026 Guidance Overhaul
On March 9, 2026, the FDA released updated guidance for biosimilar development under the Biologics Price Competition and Innovation Act (BPCIA) — and the changes are significant.
What Changed
The new guidance removes the previous requirement for comparative clinical pharmacokinetic (PK) studies in specific cases. Biosimilar developers can now:
- Forego direct PK comparisons with U.S.-licensed reference products where appropriate scientific justification exists
- Use clinical data from non-U.S.-licensed reference products in certain circumstances, streamlining global development programmes
- Rely more heavily on advanced analytical testing rather than lengthy comparative clinical efficacy studies
Why It Matters
Biologics represent 51% of drug spending despite making up only about 5% of all prescriptions. The cost of biosimilar development under the old framework was prohibitive for many developers. The new guidance is projected to reduce development costs by up to 50%, or approximately $20 million per programme — a transformative change for the biosimilar sector.
To date, the FDA has approved 82 biosimilars in the U.S. The streamlined pathway signals an intent to accelerate that number significantly.
Career Implications
Biosimilar regulatory affairs is one of the most specialised and in-demand niches in the profession. The new guidance does not reduce the need for expert regulatory knowledge — it raises the bar on analytical expertise, scientific justification writing, and cross-border regulatory strategy. Regulatory professionals with biosimilar fluency are among the highest-paid and most sought-after in the industry.
5. Medical Device Cybersecurity: Hardening the Regulatory Baseline
For medical device manufacturers, 2026 has brought an increasingly stringent approach to cybersecurity requirements in 510(k) and PMA submissions.
What the FDA Now Expects
- A Software Bill of Materials (SBOM) — a detailed inventory of software components — is required for devices with embedded software
- Manufacturers must demonstrate a post-market cybersecurity monitoring and patching plan
- Threat modelling and security testing documentation must accompany submissions
- Devices connecting to external networks or patient data systems face the highest level of scrutiny
The FDA's expectation is that cybersecurity is built into device design — not bolted on after the fact. Submissions that treat cybersecurity as an afterthought are increasingly receiving Refuse to Accept (RTA) decisions early in the review process, adding months to already pressurised timelines.
6. ESG, Environmental Disclosures, and Regulatory Governance
A less-discussed but increasingly important dimension of FDA regulatory strategy in 2026 is the growing attention to Environmental, Social, and Governance (ESG) factors in drug and device manufacturing.
While ESG regulation in the U.S. pharmaceutical space is still evolving, regulatory professionals are seeing:
- Increased scrutiny of manufacturing environmental practices during inspections
- Growing alignment with EU sustainability directives that affect global supply chains
- Pressure on sponsors to demonstrate supply chain resilience and ethical sourcing of active pharmaceutical ingredients (APIs)
- Diversity in clinical trial populations as an emerging regulatory expectation in submissions to the FDA
For industry, ESG is rapidly becoming a compliance matter — not just a PR exercise. Regulatory affairs teams are being called upon to integrate sustainability considerations into strategy and documentation in ways that were not expected even two years ago.
7. The Career Opportunity: Why the Regulatory Affairs Job Market Is Booming in 2026
Against this backdrop of complexity, it may surprise some to learn that the regulatory affairs job market in 2026 is among the strongest on record.
The Data
- The Regulatory Affairs Outsourcing Market is projected to grow from $9.43 billion in 2025 to $10.74 billion in 2026 — a CAGR of 13.9% — and is expected to reach $18.29 billion by 2030
- The Global Regulatory Affairs & Compliance market is forecast to grow from $19.3 billion (2024) to $39.2 billion by 2033
- Regulatory Affairs Specialist is consistently listed among the fastest-growing roles in life sciences, alongside Medical Affairs/MSL and Clinical Data Scientist
- North America leads with a 41.1% market share, while the Asia-Pacific region is the fastest-growing market globally
Hiring managers in 2026 are explicit about what they want: real exposure to submissions, labelling, Health Authority communications, and document support tied to actual products. Generic knowledge alone is no longer sufficient.
How to Prepare for the 2026 Regulatory Landscape: Training That Delivers Real Results
The regulatory shifts outlined in this blog are not theoretical. They are reshaping what employers expect from every regulatory professional — from entry-level associates to senior strategists. The question is: how do you get the skills that matter, fast?
Comparing Your Options
There are several paths people explore when entering regulatory affairs.
The crucial differentiator for employers in 2026 is demonstrable practical experience. Hiring managers on Reddit's regulatory affairs communities are clear: they want candidates who have worked on real submissions and regulatory documents — not just those who have completed online quizzes.
Programmes that bundle knowledge with hands-on work experience are structurally better positioned to produce job-ready graduates than self-paced courses alone.
8. Key Takeaways: What You Should Do Right Now
Whether you are a pharmaceutical company, a regulatory consultant, or someone looking to enter the profession, here is your action plan for 2026:
For industry professionals and companies:
- ✅ Build your AI governance documentation framework before you need it for a submission
- ✅ Engage the FDA early via the Q-Sub process — do not wait for the agency to clear its backlog
- ✅ Review your biosimilar development programme in light of the March 2026 guidance changes
- ✅ Conduct a cybersecurity audit of any connected medical devices ahead of your next submission
- ✅ Begin integrating RWE strategy into early development planning, not late-stage supplementation
For aspiring regulatory professionals:
- ✅ Prioritise training that includes practical, hands-on regulatory work — not just theory
- ✅ Develop competencies in AI governance, RWE methodology, and biosimilar science
- ✅ Enter the market now — the window for career-changers is wide open, and demand is outpacing supply
- ✅ Ensure your CV reflects actual regulatory document experience, not just coursework
9. Ready to Launch Your Career in Regulatory Affairs?
The FDA policy shifts of 2026 are creating a wave of demand for skilled regulatory professionals — and the supply is simply not keeping up. That gap is your opportunity.
At Entry to Regulatory, we provide training courses for anyone trying to build a career in Regulatory Affairs — no previous experience required. Our programme is specifically designed to bridge the gap between theoretical knowledge and what employers actually need in 2026 and beyond.
Here is what you get:
- 📋 50+ CPD hours covering EU, US, and UK regulatory frameworks
- 🔬 Real-life work assignments — the kind hiring managers are looking for on your CV
- 🧑💼 Job search support — including CV reviews, mock interviews, and career mentoring
- 🌐 A professional community of peers and industry connections
- 🏆 Proven results — graduates report landing roles within weeks to months of completing the course, with UK associates earning upwards of £50,000 and US roles offering $100,000+
Whether you are a career-changer, a life sciences graduate, or simply someone who wants to step into one of the most resilient and well-paid sectors in the world — we can help.
Next cohort starts: July 2026. Limited spaces available.
About the Author: Rabiea is an Honorary Associate Professor at UCL, former MHRA Health Authority reviewer, and CEO of Entry to Regulatory and Advanced Regulatory Consulting. After transitioning from retail pharmacy to regulatory affairs, she has dedicated her career to helping others make the same successful career change. Connect with her on LinkedIn for the latest regulatory affairs insights and career advice.
Comments